| | Term | Count | % | Genes |
| | Pathways in cancer | 5 | 20.84 | FLT3, CASP3, KIT, PTGS2, HRAS | | TNF signaling pathway | 4 | 16.67 | CASP7, CASP3, PTGS2, TNF | | Proteoglycans in cancer | 4 | 16.67 | CASP3, HRAS, ESR1, TNF | | MAPK signaling pathway | 4 | 16.67 | RPS6KA3, CASP3, HRAS, TNF | | HTLV-I infection | 4 | 16.67 | TERT, HRAS, TNF, IL2 | | MicroRNAs in cancer | 4 | 16.67 | CASP3, CYP1B1, PTGS2, HRAS | | Ovarian steroidogenesis | 3 | 12.50 | CYP1A1, CYP1B1, PTGS2 | | Legionellosis | 3 | 12.50 | CASP7, CASP3, TNF | | Acute myeloid leukemia | 3 | 12.50 | FLT3, KIT, HRAS | | Apoptosis | 3 | 12.50 | CASP7, CASP3, TNF | | Central carbon metabolism in cancer | 3 | 12.50 | FLT3, KIT, HRAS | | Pertussis | 3 | 12.50 | CASP7, CASP3, TNF | | Chemical carcinogenesis | 3 | 12.50 | CYP1A1, CYP1B1, PTGS2 | | Hematopoietic cell lineage | 3 | 12.50 | FLT3, KIT, TNF | | Estrogen signaling pathway | 3 | 12.50 | OPRM1, HRAS, ESR1 | | T cell receptor signaling pathway | 3 | 12.50 | HRAS, TNF, IL2 | | Serotonergic synapse | 3 | 12.50 | CASP3, PTGS2, HRAS | | Sphingolipid signaling pathway | 3 | 12.50 | OPRD1, HRAS, TNF | | Natural killer cell-mediated cytotoxicity | 3 | 12.50 | CASP3, HRAS, TNF | | Hepatitis B | 3 | 12.50 | CASP3, HRAS, TNF | | Nonalcoholic fatty liver disease (NAFLD) | 3 | 12.50 | CASP7, CASP3, TNF | | Alzheimer’s disease | 3 | 12.50 | CASP7, CASP3, TNF | | Graft-versus-host disease | 2 | 8.33 | TNF, IL2 |
|
|
